Want to see BMRA full AI Analyst Report?
Top Page
Biomerica
(NASDAQ:BMRA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$2.00
▼(-4.76% Downside)
Action:Reiterated
Date:10/16/26
BMRA’s score is primarily weighed down by weak financial performance—persistent operating losses, extremely thin gross margins, and ongoing cash burn alongside rising leverage. Technical indicators also point to bearish momentum with the price below major moving averages and a negative MACD. Valuation provides only modest offset because the negative P/E reflects continuing losses and there is no dividend yield.
Positive Factors
Positive equity cushion
Positive equity and moderate debt relative to assets provide some financial cushion while Biomerica works to improve operations. This does not remove balance-sheet risk, but it may preserve flexibility to pursue its diagnostic business and manage obligations over the next several quarters.
Negative Factors
Persistent revenue contraction
Sustained revenue contraction limits operating scale and reduces the pool from which Biomerica can fund research, sales efforts, and overhead. Without a durable recovery in product demand, the company may struggle to spread fixed costs and establish a stronger earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Positive equity cushion
Positive equity and moderate debt relative to assets provide some financial cushion while Biomerica works to improve operations. This does not remove balance-sheet risk, but it may preserve flexibility to pursue its diagnostic business and manage obligations over the next several quarters.
Read all positive factors
Biomerica (BMRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.73M
Dividend YieldN/A
Average Volume (3M)20.61K
Price to Earnings (P/E)―
Beta (1Y)2.00
Revenue Growth-11.20%
EPS Growth-6.64%
CountryUS
Employees50
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.63
Shares Outstanding4,598,968
10 Day Avg. Volume10,503
30 Day Avg. Volume20,609
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.62
Price to Sales (P/S)1.54
P/FCF Ratio-2.01
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit166.19
Enterprise Value/Ebitda-1.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biomerica Business Overview & Revenue Model
Company Description
Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases...
How the Company Makes Money
Biomerica makes money primarily by selling its diagnostic products and related consumables to customers such as clinical laboratories, hospitals/clinics, and distributors. Revenue is generally generated from (1) product sales of test kits and assa...
Biomerica Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
42
Neutral
Cash Flow
18
Very Negative
| Breakdown | Aug 2026 | May 2025 | May 2024 | May 2023 | May 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.45M | 5.31M | 5.42M | 5.34M | 18.87M |
| Gross Profit | 362.00K | 498.00K | 611.00K | 446.00K | 2.98M |
| EBITDA | -4.90M | -4.57M | -5.56M | -6.74M | -3.94M |
| Net Income | -3.77M | -4.97M | -5.98M | -7.14M | -4.53M |
Balance Sheet | |||||
| Total Assets | 6.76M | 5.95M | 9.25M | 14.45M | 11.37M |
| Cash, Cash Equivalents and Short-Term Investments | 1.31M | 2.40M | 4.17M | 9.72M | 5.92M |
| Total Debt | 2.38M | 458.00K | 785.00K | 1.08M | 1.38M |
| Total Liabilities | 4.13M | 1.84M | 2.66M | 2.73M | 3.05M |
| Stockholders Equity | 2.63M | 4.11M | 6.59M | 11.72M | 8.32M |
Cash Flow | |||||
| Free Cash Flow | -3.42M | -3.88M | -5.48M | -5.55M | -650.87K |
| Operating Cash Flow | -3.42M | -3.84M | -5.36M | -5.47M | -480.53K |
| Investing Cash Flow | -1.00K | -37.00K | -115.00K | -78.00K | -170.34K |
| Financing Cash Flow | 2.33M | 2.11M | -81.00K | 9.39M | 2.39M |
Biomerica Technical Analysis
Negative
2.10
Price Trends
2.05
Negative
1.90
Negative
2.07
Negative
Market Momentum
-0.13
Positive
32.31
Neutral
25.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMRA, the sentiment is Negative. The current price of 2.1 is above the 20-day moving average (MA) of 1.95, above the 50-day MA of 2.05, and above the 200-day MA of 2.07, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 32.31 is Neutral, neither overbought nor oversold. The STOCH value of 25.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMRA.
Biomerica Risk Analysis
Biomerica disclosed 33 risk factors in its most recent earnings report. Biomerica reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biomerica Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $15.60M | -0.98 | -816.25% | ― | -27.70% | 61.44% | |
45 Neutral | $7.73M | -1.03 | -142.81% | ― | -11.20% | -6.64% | |
43 Neutral | $1.18K | ― | -268.41% | ― | -8.54% | 40.91% | |
42 Neutral | $17.35M | -0.13 | -33.51% | ― | -89.02% | -107.75% | |
40 Underperform | $4.74M | -0.05 | -267.73% | ― | ― | 64.78% |
* Healthcare Sector Average
BMRA
Biomerica
1.68
-1.28
-43.24%
SSKN
Strata Skin Sciences
0.09
-1.59
-94.64%
PAVM
PAVmed
2.17
-11.27
-83.85%
HSCS
Heart Test Laboratories, Inc.
3.14
-0.10
-3.09%
AMIX
Autonomix Medical, Inc.
2.42
-21.31
-89.80%
Biomerica Corporate Events
Executive/Board ChangesShareholder Meetings
Biomerica Announces Board and Governance Committee Transition
Neutral
Oct 15, 2026
On October 12, 2026, Biomerica, Inc. disclosed that director David Moatazedi will not stand for re-election at the company’s 2026 Annual Meeting of Stockholders, scheduled for December 11, 2026. Moatazedi, who joined the Board in December 20...
Private Placements and FinancingRegulatory Filings and Compliance
Biomerica Completes Private Placement of Equity Securities
Positive
Aug 26, 2026
On August 20, 2026, Biomerica entered into a securities purchase agreement with institutional and individual investors, including B. Riley Principal Capital and certain directors and executives, to sell 1,393,705 common shares at $1.60 each, raisi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.